| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |


* Fellow, Program in Critical Care Medicine and Respirology, and
the Departments of Medicine and
Anesthesia and Perioperative Medicine, University of Western Ontario, London, Ontario, Canada.
Address correspondence to: Dr. Michael D. Sharpe, Department of Anesthesia and Perioperative Medicine, London Health Sciences Centre, University Campus, 339 Windermere Rd, London, Ontario N6A 5A5, Canada. Phone: 519-663-3030; Fax: 519-663-3150; E-mail: michael.sharpe{at}lhsc.on.ca
| Abstract |
|---|
|
|
|---|
Clinical findings: A 35-yr-old healthy male presented with abdominal pain and blurred vision 12 hr after ingesting a "bad" potato. During the next 17 hr, the patient demonstrated a gradual descending paralysis which ultimately resulted in no cranial nerve function and 0/5 strength in all extremities. Sensation was intact. The patient required intubation and mechanical ventilation. His blood count, biochemical profile, computerized tomography and magnetic resonance imaging of the head were normal. A lumbar puncture revealed no abnormalities. Due to the rapid deterioration and presentation of descending paralysis, botulism was suspected. The patient was treated empirically with botulinum anti-toxin. Samples of blood, stool and gastric contents were cultured for the presence of Clostridium botulinum and its toxin and these tests were positive for botulinum toxin A 12 days later. The patients neuromuscular function gradually improved over a prolonged period of time. Six and one-half months after his initial presentation, the patient was discharged home after completing an aggressive rehabilitation program.
Conclusions: Botulism is a rare syndrome and presents as an acute, afebrile, descending paralysis beginning with the cranial nerves. If suspected, botulinum anti-toxin should be considered, particularly within the first 24 hr of onset of symptoms. Confirmation of the presence of botulinum requires days therefore the diagnosis and management rely on history and physical examination.
| Introduction |
|---|
|
|
|---|
| Case report |
|---|
|
|
|---|
Because of the rapid deterioration of a descending paralysis following the ingestion of a spoiled potato, botulism was strongly suspected. Cultures of blood, stool, gastric contents, and samples of food from the restaurant were sent for analysis for the presence Clostridium botulinum and its toxin. Unfortunately, the implicated potato was not available for testing. The decision was made to treat the patient for possible botulism poisoning and the botulism anti-toxin (Botulism Anti-toxin Trivalent (Equine) types A, B and E, Aventis Pasteur Limited, Toronto, ON, Canada) was administered after skin testing for hypersensitivity without any important adverse effect. The patient did not have any further neurological deterioration after the administration of the anti-toxin.
Results of the cultures and the toxin studies returned positive for both Clostridium botulinum and botulinum toxin A approximately 12 days after admission. The patient had a prolonged course in the ICU with a slow neuromuscular recovery. He was treated for an aspiration pneumonia during the first week of admission. He eventually required a tracheostomy and a gastro-jejunostomy feeding tube for respiratory and nutritional support, respectively. Upon discharge to his local hospital, the patient was able to open and close his eyes, had 12/5 strength in the upper extremities and could withdraw his lower extremities. Approximately six and one-half months after initial presentation, the patient was discharged home after completing an aggressive rehabilitation program in his local hospital. He did not have any requirements for long-term care. The local health department investigating this case reported no other cases.
| Discussion |
|---|
|
|
|---|
The classical presentation of Clostridium botulism is one of an acute, afebrile, descending paralysis beginning with cranial nerve abnormalities as early as eight hours after exposure. There are no sensory deficits and deep tendon reflexes may be preserved early on. Depending on the route of infection, a prodrome of nausea, vomiting and diarrhea may occur. In infants, poor feeding, lethargy, a weak cry, decreased sucking and lack of muscle tone may be presenting signs.
The differential diagnosis of a patient who presents with acute neuromuscular dysfunction is broad (Table
). The history and physical examination are important in helping discern the etiology of a patients illness, as are the appropriate investigations. Initial investigations in patients who present with acute neuromuscular disease should include complete blood count, electrolytes, creatinine, blood urea nitrogen, glucose, cultures of appropriate body fluids, electromyography, chest radiography, computerized tomography and magnetic resonance imaging of appropriate anatomy and analysis for botulinum toxin if suspected by the history and presentation. Toxin type is identified by injecting mice with the source of botulism toxin and various type specific anti-toxins are administered to determine which prevents death.6 ELISA and PCR testing to replace this method remain controversial.7 Electromyography is also helpful in the diagnosis, with the most common finding with botulism poisoning being small evoked potentials in response to a single maximal stimulus.8
|
Other therapeutic modalities have been considered but little evidence supports their use. Antibiotics for wound botulism is recommended by some for adjunctive therapy with anti-toxin and wound debridement. Aminoglycosides should not be used in any capacity, as they have been shown to potentiate the neuromuscular blockade, especially in infants.14 Other considerations include the use of laxatives, enemas and other cathartics in foodborne botulism, provided there is no significant ileus present. Induced vomiting and gastric lavage may be considered if ingestion is recent; no evidence exists supporting the use of activated charcoal. In addition, patients may require significant supportive care including ventilation, nutrition, physiotherapy and occupational therapy. Patients are expected to survive their illness, but persistence and vigilance on the part of the health care team is required.
Botulism, although a rare illness, is treatable and reversible but requires the physician to be thoughtful of it as a possible etiology of disease. Its presentation is dramatic and its effects are severe and debilitating. Effectiveness of treatment depends on early recognition and administration of anti-toxin. Clostridium botulinum is one of many potential biological weapons that are of global concern and, in these unsettled times, it may be an illness requiring our attention. Clostridium botulinum is a reportable disease and all cases should be referred to Health Canada Botulism Reference Service for Canada. Early communication may limit the spread of a very serious disease process.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2 Hatheway CL. Botulism: the present status of the disease. Curr Top Microbiol Immunol 1995; 195: 5575.[Medline]
3 Public Health Agency of Canada. Canadian Communicable Disease Report. URL available at: www.phac-aspc.gc.ca. 1996; 22: 21.
4 Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon. Medical and public health management. JAMA 2001; 285: 105970.
5 Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399411.[Abstract]
6 Hatheway CL. Botulism. In: Balows A, Hausler WH, Lennette EH (Eds). Laboratory Diagnosis of Infectious Diseases: Principles and Practice, Vol 1. New York: Springer-Verlag; 1988: 111.
7 Szabo EA, Pemberton JM, Gibson AM, Eyles MJ, Desmarchelier PM. Polymerase chain reaction for detection of Clostridium botulinum types A, B and E in food, soil and infant faeces. J Appl Bacteriol 1994; 76: 53945.[Medline]
8 Cherington M. Clinical spectrum of botulism. Muscle Nerve 1998; 21: 70110.[Medline]
9 Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE Jr. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B and E. J Infect Dis 1984; 150: 40712.[Medline]
10 Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984; 76: 7948.[Medline]
11 Chang GY, Ganguly G. Early antitoxin treatment in wound botulism results in better outcome. Eur Neurol 2003; 49: 1513.[Medline]
12 Sandrock CE, Murin S. Clinical predictors of respiratory failure and long-term outcome in black tar heroin-associated wound botulism. Chest 2001; 120: 5626.
13 Hibbs RG, Weber JT, Corwin A, et al. Experience with the use of an investigational F(ab) heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis 1996; 23: 33740.[Medline]
14 Santos JI, Swensen P, Glasgow LA. Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 1981; 68: 504.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |